Results from the POLARGO trial “reinforce the benefit of adding polatuzumab to chemoimmunotherapy,” said Matthew Matasar, MD.

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return ...

Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected ...

SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those ...